Call Options

17 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$1.75 - $3.96 $23,975 - $54,252
-13,700 Reduced 48.41%
14,600 $1,000
Q3 2022

Nov 14, 2022

BUY
$3.09 - $7.46 $21,630 - $52,220
7,000 Added 32.86%
28,300 $3,000
Q2 2022

Aug 12, 2022

SELL
$1.92 - $6.28 $42,816 - $140,044
-22,300 Reduced 51.15%
21,300 $8,000
Q1 2022

May 12, 2022

SELL
$5.07 - $7.2 $1.67 Million - $2.37 Million
-329,800 Reduced 88.32%
43,600 $32,000
Q4 2021

Feb 14, 2022

BUY
$5.67 - $8.54 $132,111 - $198,981
23,300 Added 6.66%
373,400 $36,000
Q3 2021

Nov 10, 2021

SELL
$13.4 - $16.3 $10,720 - $13,040
-800 Reduced 0.23%
350,100 $682,000
Q2 2021

Aug 11, 2021

BUY
$14.81 - $19.13 $19,253 - $24,869
1,300 Added 0.37%
350,900 $910,000
Q1 2021

May 14, 2021

BUY
$14.52 - $23.53 $53,724 - $87,061
3,700 Added 1.07%
349,600 $1.61 Million
Q4 2020

Feb 16, 2021

BUY
$10.14 - $15.19 $2.8 Million - $4.19 Million
275,900 Added 394.14%
345,900 $1.17 Million
Q3 2020

Nov 13, 2020

BUY
$9.57 - $21.32 $560,802 - $1.25 Million
58,600 Added 514.04%
70,000 $58,000
Q2 2020

Aug 10, 2020

BUY
$12.21 - $16.99 $139,194 - $193,685
11,400 New
11,400 $19,000
Q1 2020

May 08, 2020

SELL
$9.03 - $19.72 $189,630 - $414,120
-21,000 Closed
0 $0
Q4 2019

Feb 11, 2020

BUY
$13.01 - $17.15 $35,127 - $46,304
2,700 Added 14.75%
21,000 $9,000
Q3 2019

Nov 12, 2019

BUY
$14.55 - $20.56 $75,660 - $106,912
5,200 Added 39.69%
18,300 $25,000
Q2 2019

Aug 14, 2019

BUY
$15.0 - $19.62 $196,500 - $257,022
13,100 New
13,100 $17,000
Q1 2019

May 10, 2019

SELL
$11.65 - $17.72 $1.22 Million - $1.86 Million
-105,100 Closed
0 $0
Q4 2018

Feb 12, 2019

BUY
$10.72 - $16.73 $1.13 Million - $1.76 Million
105,100 New
105,100 $62,000

Others Institutions Holding OMER

About OMEROS CORP


  • Ticker OMER
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,730,000
  • Market Cap $684M
  • Description
  • Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...
More about OMER
Track This Portfolio

Track Hap Trading, LLC Portfolio

Follow Hap Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hap Trading, LLC with notifications on news.